Recombinate (Hemophilia A and B)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis and Quality of Life 14
3.2 Symptoms 15
3.2.1 Hemophilia A and B 15
3.2.2 Inhibitors 16
4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Hemophilia A and B Diagnosis 18
4.1.2 Hemophilia A and B Treatment 18
4.1.3 Inhibitors Diagnosis 20
4.1.4 Inhibitors Treatment 20
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitive Assessment 23
6 Recombinate (octocog alfa) 27
6.1 Overview 27
6.2 Efficacy 28
6.3 Safety 28
6.4 SWOT Analysis 28
6.5 Forecast 29
7 Appendix 30
7.1 Bibliography 30
7.2 Abbreviations 32
7.3 Methodology 34
7.4 Forecasting Methodology 35
7.4.1 Diagnosed Hemophilia Patients 35
7.4.2 Percent Drug-Treated Patients 35
7.4.3 General Pricing Assumptions 36
7.4.4 Individual Drug Assumptions 36
7.5 About the Authors 39
7.5.1 Authors 39
7.5.2 Global Head of Healthcare 40
7.6 About GlobalData 41
7.7 Disclaimer 41